ID: ALA5203639

Max Phase: Preclinical

Molecular Formula: C20H17ClN4O3S

Molecular Weight: 428.90

Representations

Canonical SMILES:  O=C(Nc1ccc(Cl)cc1[N+](=O)[O-])N1CCC[C@H]1c1nc(-c2ccccc2)cs1

Standard InChI:  InChI=1S/C20H17ClN4O3S/c21-14-8-9-15(18(11-14)25(27)28)23-20(26)24-10-4-7-17(24)19-22-16(12-29-19)13-5-2-1-3-6-13/h1-3,5-6,8-9,11-12,17H,4,7,10H2,(H,23,26)/t17-/m0/s1

Standard InChI Key:  XLTBTZYINHOHKS-KRWDZBQOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 428.90

Molecular Weight (Monoisotopic): 428.0710

AlogP: 5.74

#Rotatable Bonds: 4

Polar Surface Area: 88.37

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 10.64

CX Basic pKa: 1.06

CX LogP: 4.98

CX LogD: 4.98

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.42

Np Likeness Score: -1.86

References

1. Qiao Y, Zhang Y, Qiao Z, He W, Chen Y, Song D, Wang G, Guo N, Shao L, Tian Z, Wang Q, Yan L, Qian H..  (2022)  Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist.,  233  [PMID:35263708] [10.1016/j.ejmech.2022.114191]

Source

Source(1):

• Scientific Literature